id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1999-D-0050-0003,FDA,FDA-1999-D-0050,Guidance for Industry; Bioavailability & Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action,Other,Guidance,2008-11-17T05:00:00Z,2008,11,,,2025-06-04T18:12:09Z,,1,0,09000064804a609b
FDA-1999-D-0050-0002,FDA,FDA-1999-D-0050,Draft Guidance for Industry; Bioavailability & Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action; Availability,Notice,Notice of Data Availability,2003-04-09T04:00:00Z,2003,4,2003-04-09T04:00:00Z,2003-07-03T03:59:59Z,2025-06-04T18:23:46Z,03-8010,0,0,09000064804a609c
FDA-1999-D-0050-0001,FDA,FDA-1999-D-0050,Draft Guidance for Industry on Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action; Availability,Notice,Notice of Data Availability,1999-06-25T04:00:00Z,1999,6,1999-06-25T04:00:00Z,1999-09-23T03:59:59Z,2025-06-05T09:00:08Z,99-16140,0,0,09000064804a6066